Thermo Fisher Scientific

Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 12, 2021

The "Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2020-30: COVID 19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2020-30: COVID 19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • This report focuses on lateral flow immunoassay (LFIA) based rapid test market which is experiencing strong growth.
  • The lateral flow immunoassay (LFIA) based rapid test market consists of sales of devices and equipment used to run lateral flow immunoassays (LFIA) based rapid test and related services by companies that develop lateral flow immunoassays (LFIA) based rapid test equipment.
  • Therefore, the need for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market.

Fetal Bovine Serum Global Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 11, 2021

The "Fetal Bovine Serum Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fetal Bovine Serum Global Market Report 2021: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.
  • The global fetal bovine serum market is expected to grow from $855.80 million in 2020 to $946.25 million in 2021 at a compound annual growth rate (CAGR) of 10.6%.
  • The fetal bovine serum market consists of sales of fetal bovine serum by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing fetal bovine serum and related services.
  • The main types of fetal bovine serum are charcoal stripped, chromatographic, dialyzed fetal bovine serum, exosome depleted, stem cell, others.

Worldwide Molecular Quality Controls Industry to 2028 - Rise in Adoption of Molecular Diagnostics Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 10, 2021

According to the WHO suggestions, 30-50% of deaths caused due to cancer can be prevented by adequate treatment in early stages.

Key Points: 
  • According to the WHO suggestions, 30-50% of deaths caused due to cancer can be prevented by adequate treatment in early stages.
  • The increasing adoption of personalized medicines, based on patient's genetic information, for disease treatments is expected to favor the growth of the molecular quality controls market in the coming years.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the molecular quality controls market.
  • The key findings and recommendations highlight crucial progressive industry trends in the global molecular quality controls market, thereby allowing players across the value chain to develop effective long-term strategies.

Kaleido Biosciences Announces New Chairperson Appointment to its Board of Directors

Retrieved on: 
Monday, August 9, 2021

Concurrently Michael (Mike) Bonney has resigned from the Board of Directors and his position as Chairperson due to increased demands from other business obligations.

Key Points: 
  • Concurrently Michael (Mike) Bonney has resigned from the Board of Directors and his position as Chairperson due to increased demands from other business obligations.
  • I am delighted that Theo has taken on the role of Chairperson of the Board said Dan Menichella, President and Chief Executive Officer of Kaleido.
  • As a board member, Theo has contributed significantly to Kaleido, drawing on his deep experience in financial and corporate strategy and expertise in building life sciences companies.
  • Mike has been a delight to work alongside and learn from, and I am honored to succeed him as Kaleidos Chairperson, said Mr. Melas-Kyriazi.

Consortium for Top-Down Proteomics Launches New Initiative for the CE-MS of Intact Proteins and Protein Complexes

Retrieved on: 
Monday, August 9, 2021

One of the greatest challenges in analyzing intact proteins and protein complexes is the efficient separation of mixtures into their constituents before analysis by MS.

Key Points: 
  • One of the greatest challenges in analyzing intact proteins and protein complexes is the efficient separation of mixtures into their constituents before analysis by MS.
  • The high resolution provided by CE will be particularly valuable in separating various proteoforms and non-covalent protein complexes present in biological and biopharmaceutical samples.
  • The Initiative is being led by Liangliang Sun of Michigan State University, Alexander R. Ivanov of Northeastern University, and Kevin Jooss of Northwestern University.
  • The Initiative will evaluate the current state of the art using mixtures of proteins and protein complexes that are separated with CE and then measured online for intact mass as well as structural fragments by MS.

Global Proteomics Market to 2026 - Analysis By Component (Instruments, Reagents, Services), & Application (Clinical Diagnostic, Drug Discovery, Others) - ResearchAndMarkets.com

Retrieved on: 
Monday, August 9, 2021

The Global Proteomics Market is estimated at USD 3.49 Billion in the year 2020, growing at a CAGR of 7% for the period spanning 2021-2026.

Key Points: 
  • The Global Proteomics Market is estimated at USD 3.49 Billion in the year 2020, growing at a CAGR of 7% for the period spanning 2021-2026.
  • The report presents the analysis of Proteomics market for the historical period 2016-2020 and forecast period of 2021-2026.
  • Proteomics market growth is driven by rise in popularity of personalized medicines, surge in R&D expenditure, and technological advancements associated with proteomics components.
  • Conversely, lucrative opportunities associated with biomarker identification and developments in mass spectrometry-based proteomics are expected to provide lucrative growth opportunities for the proteomics market growth.

Animal Pregnancy Test Kit Market Report 2021 - Global Growth, Trends, and Forecasts to 2026 with IDEXX, Fassisi, Biotracking, Zoetis Services, and Thermo Fisher Scientific Dominating - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 5, 2021

The "Animal Pregnancy Test Kit Market - Growth, Trends, Covid-19 Impact, And forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Animal Pregnancy Test Kit Market - Growth, Trends, Covid-19 Impact, And forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
  • The animal pregnancy test kit market is expected to grow with an estimated CAGR of 4.5 % over the forecasts period.
  • Many global players are expected to be part of the animal pregnancy test kit over the forecasts period.
  • Some of the major players of the market are IDEXX, Fassisi, Biotracking, Zoetis services, and Thermo Fisher Scientific.

PHC Holdings Corporation: Appointment of Mr. Alan Malus and Ms. Kyoko Deguchi as Independent External Directors

Retrieved on: 
Wednesday, July 28, 2021

PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: John Marotta, hereafter PHCHD), a leading global healthcare company, has today announced the appointment of Alan Malus and Kyoko (Kay) Deguchi as independent external directors, effective June 30, 2021.

Key Points: 
  • PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: John Marotta, hereafter PHCHD), a leading global healthcare company, has today announced the appointment of Alan Malus and Kyoko (Kay) Deguchi as independent external directors, effective June 30, 2021.
  • Mr. Malus joins the board with over 18 years experience in the life sciences and diagnostics industry.
  • Mr. Malus was most recently Corporate Executive Vice President at Thermo Fisher Scientific Inc. and the President of their Laboratory Products and Services Segment.
  • PHC Holdings Corporation is a global healthcare company with subsidiaries including PHC Corporation, Ascensia Diabetes Care, Epredia, and LSI Medience Corporation.

INOVIO to Report Second Quarter 2021 Financial Results on August 9, 2021

Retrieved on: 
Monday, July 26, 2021

PLYMOUTH MEETING, Pa., July 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2021 financial results will be released after the market close on August 9, 2021.

Key Points: 
  • PLYMOUTH MEETING, Pa., July 26, 2021 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that second quarter 2021 financial results will be released after the market close on August 9, 2021.
  • Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m.
  • ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's ongoing vaccine developments for COVID-19.
  • A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx .

Berkeley Lights announces technology collaboration to accelerate and improve gene therapy viral vector development and manufacturing

Retrieved on: 
Wednesday, July 21, 2021

EMERYVILLE, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI) today announced a strategic collaboration with Thermo Fisher Scientific aimed at addressing challenges in commercial-scale viral vector manufacturing.

Key Points: 
  • EMERYVILLE, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI) today announced a strategic collaboration with Thermo Fisher Scientific aimed at addressing challenges in commercial-scale viral vector manufacturing.
  • The partnership, which began in December of 2020, brings together Berkeley Lights leadership in functional biology characterization with Thermo Fishers expertise in viral vector manufacturing and analytics.
  • Together, the companies are collaborating on a next-generation workflow using the Berkeley Lights Platform to accelerate and improve the development of stable AAV (Adeno-Associated Viral) and LV (Lentiviral) vector producer cell lines.
  • This effort builds on the foundation of Thermo Fishers viral vector manufacturing and development experience, and the Berkeley Lights OptoTM Assure Cell Line Development workflow that is focused on identifying clones with high product yield and favorable manufacturability profiles early in cell line development.